|
Adverse events reported by at least 5% of patients in any group during the IR or SR phase |
||||
| IR phase |
SR phase |
|||
|
|
||||
| Adverse event |
Hydromorphone (N = 99) |
Morphine (N = 101) |
OROS® hydromorphone (N = 77) |
CR morphine (N = 86) |
|
|
||||
| Constipation |
23 (23.2%) |
11 (10.9%) |
30 (39.0%) |
19 (22.1%) |
|
|
||||
| Nausea |
18 (18.2%) |
23 (22.8%) |
15 (19.5%) |
25 (29.1%) |
|
|
||||
| Vomiting |
16 (16.2%) |
19 (18.8%) |
7 (9.1%) |
19 (22.1%) |
|
|
||||
| Somnolence |
11 (11.1%) |
11 (10.9%) |
8 (10.4%) |
12 (14.0%) |
|
|
||||
| Dizziness |
8 (8.1%) |
6 (5.9%) |
4 (5.2%) |
8 (9.3%) |
|
|
||||
| Headache |
8 (8.1%) |
6 (5.9%) |
3 (3.9%) |
2 (2.3%) |
|
|
||||
| Diarrhea |
8 (8.1%) |
1 (1.0%) |
7 (9.1%) |
2 (2.3%) |
|
|
||||
| Pruritus |
4 (4.0%) |
5 (5.0%) |
3 (3.9%) |
5 (5.8%) |
|
|
||||
| Asthenia |
5 (5.1%) |
1 (1.0%) |
6 (7.8%) |
4 (4.7%) |
|
|
||||
| Fatigue |
3 (3.0%) |
3 (3.0%) |
4 (5.2%) |
6 (7.0%) |
|
|
||||
| Confusion |
2 (2.0%) |
2 (2.0%) |
7 (9.1%) |
2 (2.3%) |
|
|
||||
| Anemia |
2 (2.0%) |
1 (1.0%) |
3 (3.9%) |
6 (7.0%) |
|
|
||||
| Anorexia |
1 (1.0%) |
4 (4.0%) |
2 (2.6%) |
5 (5.8%) |
|
|
||||
| Insomnia |
1 (1.0%) |
2 (2.0%) |
5 (6.5%) |
4 (4.7%) |
|
|
||||
| Peripheral edema |
0 |
3 (3.0%) |
1 (1.3%) |
8 (9.3%) |
|
|
||||
| Pyrexia |
2 (2.0%) |
1 (1.0%) |
4 (5.2%) |
2 (2.3%) |
|
|
||||
| Anxiety |
1 (1.0%) |
1 (1.0%) |
5 (6.5%) |
1 (1.2%) |
|
Abbreviations: CR, controlled-release; IR, immediate-release; SR, sustained-release | ||||
Hanna et al. BMC Palliative Care 2008 7:17 doi:10.1186/1472-684X-7-17 |
||||